Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: The optimal number of 3-wk docetaxel plus prednisone (DP) cycles for metastatic castration-resistant prostate cancer (mCRPC) is unclear. OBJECTIVE: A retrospective analysis of two clinical trials was performed to evaluate the association of the number of cycles with overall survival (OS)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Pond, Gregory R., Armstrong, Andrew J., Wood, Brian A., Brookes, Melissa, Leopold, Lance, Berry, William R., de Wit, Ronald, Eisenberger, Mario A., Tannock, Ian F., Sonpavde, Guru
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483076/
https://ncbi.nlm.nih.gov/pubmed/21715086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2011.06.034
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia